Form 4: Haemonetics Corp Executive Roy Galvin Reports Stock Transaction

Roy Galvin, President, Global Plasma & BC at Haemonetics Corp, reports disposition of shares to cover tax obligations and acquisition of shares through an employee stock purchase plan.

Summary

• On November 1, 2024, Roy Galvin, President, Global Plasma & BC of Haemonetics Corp, reported a transaction involving the company's common stock.
• 161 shares were disposed of to cover tax obligations related to the vesting of restricted stock units at a price of $71.48 per share.
• Following the transaction, Galvin directly owns 7,373 shares of Haemonetics Corp.
• This number includes unvested RSUs previously reported as well as 124 shares acquired by the reporting person under the Issuer's 2007 Employee Stock Purchase Plan (as amended) on October 31, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing reflects routine transactions related to executive compensation and employee benefits.

Positives

• Galvin's participation in the Employee Stock Purchase Plan demonstrates confidence in the company's future.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates transactions related to compensation and employee benefits.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it involves a small number of shares.

Key Dates